Home>Topics>Companies>Sanofi S.A.

Sanofi S.A.

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. Can Once Daily GLP-1 Lyxumia Be The Next Major Growth Driver For Sanofi ?


    Wed, 16 Apr 2014

    By Pharma Intelligence : Lyxumia (lixisenatide) for the treatment of type 2 diabetes is once-daily GLP-1 from Sanofi 's ( SAN ) stable. It is a potential head to head competitor to Novo Nordisk's ( NVO ) Victoza ($2.1b - 2013 annual sales

  2. In A Shaky Biotech Market, Alnylam's Prospects Are Getting Stronger


    Tue, 8 Apr 2014

    exceed its target of having five compounds in human studies by the end of 2015 ("5 x 15"), and a recent deal with Sanofi ( SNY ) gives Alnylam development funding, a motivated commercial partner, and the perception that it has been vetted by

  3. Genzyme to resubmit Lemtrada application


    Mon, 7 Apr 2014

    Sanofi 's ( SNY ) subisidiary plans to resubmit its sBLA for Lemtrada this quarter. It believes that it has addressed all the issues the FDA raised in its December 27 CRL . It will not pursue its previously-announced appeal of the FDA's decision. ( GCVRZ ) 1 comment!

  4. After Bristol Myers' Bydureon Success, The Next Step Is Sustained Release Insulin


    Wed, 2 Apr 2014

    producing these products include, Eli Lilly ( LLY ), Merck ( MRK ), P&G, Novartis ( NVS ), AstraZeneca ( AZN ), Sanofi - Aventis ( SNY ), Allergan ( AGN ) and Bausch & Lomb. Here's a quick rundown. Sustained Release Success Across Many Disease

  5. Makings of a Wide Moat in Diabetes Care


    Fri, 28 Mar 2014

    compound annual growth rate, and we think undervalued Sanofi SNY is well-positioned to benefit from the demographic ..... well above its weighted average cost of capital. Sanofi SNY On the pipeline, Sanofi is making strides, which increases our confidence

  6. Sanofi bets big on dengue vaccine


    Tue, 25 Mar 2014

    Despite disappointing early trials data, Sanofi ( SNY ) rolls the dice and starts production of its dengue fever vaccine . The firm has invested more than 300 million euros in a manufacturing

  7. Sanofi jumps into fray for Merck's OTC unit


    Tue, 25 Mar 2014

    Sanofi ( SNY ) has joined the auction for Merck's ( MRK ) over-the-counter health-products ..... says Barclays. Merck's unit would be a "good fit" geographically for Sanofi , as 70% of its revenue comes from the U.S. Other interested parties

  8. Sanofi teams up with South Korean group on pneumococcal vaccine


    Wed, 19 Mar 2014

    PARIS, March 19 (Reuters) - French drugmaker Sanofi said its Sanofi Pasteur unit had signed a long-term cooperation deal with South Korea's SK Chemical Co to develop and market a vaccine against pneumococcal infection.

  9. Big pharma racing to develop new asthma drugs


    Tue, 18 Mar 2014

    current leader considering the long-term success of Ventolin, but Roche ( OTCQX:RHHBY ), AstraZeneca ( AZN ), Sanofi ( SNY ) and Teva (TEVA) all plan to compete in the space. Novel antibody-based drugs target key inflammatory chemicals

  10. New Morningstar Analyst Report for Sanofi

    Stock Reports

    Fri, 14 Mar 2014

    Sanofi 's strong ..... should mean Sanofi will have ..... insulin market, Sanofi 's Lantus ..... lifestyles. Sanofi 's increasingly ..... exemplary. Since Chris Viehbacher took over ..... understanding of Sanofi 's home country ..... May 2010, Serge Weinberg took over

« Prev12345Next »
Content Partners